drugset / Trial / NCT05735275
A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.
NaSingle-groupOpen-labelTreatment
Summary
This is a first in human, open-label, single-arm, multicenter dose escalation and expansion Phase 1 study of SHR-A2102 in patients with advanced or metastatic solid tumors. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A2102 and preliminary anti-tumor efficacy
Timeline
- Start
- 2023-03-03
- Primary completion
- 2025-08-31
- Completion
- 2025-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-A2102 | Other / unclassified | — | — |
Indications
No indication recorded.